Results of a randomized phase 3 study of oral sapacitabine in elderly patients with newly diagnosed acute myeloid leukemia (SEAMLESS)

Fecha de publicación: Fecha Ahead of Print:

Autores de IIS La Fe

Participantes ajenos a IIS La Fe

  • Kantarjian, Hagop M.
  • Begna, Kebede H.
  • Altman, Jessica K.
  • Goldberg, Stuart L.
  • Sekeres, Mikkael A.
  • Strickland, Stephen A.
  • Arellano, Martha L.
  • Claxton, David F.
  • Baer, Maria R.
  • Gautier, Marc
  • Berman, Ellin
  • Seiter, Karen
  • Solomon, Scott R.
  • Schiller, Gary J.
  • Luger, Selina M.
  • Butrym, Aleksandra
  • Gaidano, Gianluca
  • Thomas, Xavier G.
  • Rizzieri, David A.
  • Quick, Donald P.
  • Venugopal, Parameswaran
  • Gaur, Rakesh
  • Maness, Lori J.
  • Kadia, Tapan M.
  • Ravandi, Farhad
  • Buyse, Marc E.
  • Chiao, Judy H.

Grupos

Abstract

Acute myeloid leukemia (AML) is fatal in elderly patients who are unfit for standard induction chemotherapy. The objective of this study was to evaluate the survival benefit of administering sapacitabine, an oral nucleoside analogue, in alternating cycles with decitabine, a low-intensity therapy, to elderly patients with newly diagnosed AML.

Datos de la publicación

ISSN/ISSNe:
0008-543X, 1097-0142

CANCER  WILEY-BLACKWELL

Tipo:
Article
Páginas:
4421-4431
PubMed:
34424530
Factor de Impacto:
2,463 SCImago
Cuartil:
Q1 SCImago

Citas Recibidas en Web of Science: 4

Documentos

  • No hay documentos

Métricas

Filiaciones mostrar / ocultar

Keywords

  • acute myeloid leukemia (AML), decitabine, hypomethylation, sapacitabine, therapy

Campos de Estudio

Cita

Compartir